<DOC>
	<DOCNO>NCT02922426</DOCNO>
	<brief_summary>This study characterize insulin sensitivity response treatment ALKS 3831 , olanzapine , placebo .</brief_summary>
	<brief_title>An Insulin Sensitivity Study Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Body Mass Index ( BMI ) 18.0 &lt; 25.0 kg/m^2 screen randomization No prior history regular smoking nicotine use Women childbearing potential stable regimen oral contraceptive least 2 month prior screen Subjects must willing avoid regular exercise regimen screen end treatment period Additional criterion may apply Has current evidence history clinically significant medical psychiatric condition observe abnormality Is currently pregnant breastfeeding , plan become pregnant study Has lifetime history diabetes Has know risk narrowangle glaucoma Has clinically significant illness within 30 day prior screen admission clinic Has history dependence substance caffeine Has current anticipate need prescribe opioid medication ( eg , plan surgery ) study period Has positive urine drug screen drug abuse screen admission study site Has serious infection ( eg , pneumonia septicemia ) within 3 month prior screen admission clinic Has vaccination 4 week prior screen admission clinic Chronic use nonsteroid antiinflammatory drug ( NSAIDs ) acetaminophen , except lowdose Aspirin allow Use new prescription nonprescription drug , well dietary/nutritional supplement within 3 week precede first dose study drug , unless approve Investigator Has prior use antipsychotic medication , include label us Additional criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>ALKS 3831</keyword>
	<keyword>Samidorphan</keyword>
	<keyword>Olanzapine</keyword>
</DOC>